Tofacitinib and TNF inhibitors demonstrated similar efficacy for managing RA at 12 months, with minor differences noted across tofacitinib treatment lines.

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

New Delhi: Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Study: Tofacitinib Mitigates the Increased SARS-CoV-2 Infection Susceptibility Caused by an IBD Risk Variant in the PTPN2 Gene. Image Credit: GB.JSTOCK / Shutterstock.com A recent study published ...